<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05039268</url>
  </required_header>
  <id_info>
    <org_study_id>ZZ-3K3A-202</org_study_id>
    <nct_id>NCT05039268</nct_id>
  </id_info>
  <brief_title>3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <official_title>A Phase 2 Open Label Trial of 3K3A-APC in Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Macquarie University, Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZZ Biotech, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Macquarie University, Australia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2 open label trial to investigate the safety and potentially efficacy of 3K3A-APC in&#xD;
      patients with Amyotrophic Lateral Sclerosis (ALS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 2 open label trial seeks to investigate whether a novel therapy named 3K3A-APC is&#xD;
      safe and potentially effective in patients with Amyotrophic Lateral Sclerosis (ALS). A total&#xD;
      of 16 patients with ALS will be enrolled into 2 dose cohorts with five doses of 15mg or 30mg&#xD;
      doses given 12 hours apart in each cohort. The primary study outcomes are to ensure the&#xD;
      safety and tolerability of 3K3AAPC in ALS patients, and to determine whether 3K3A-APC is able&#xD;
      to reduce the pathological changes that might possibly cause ALS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Assessment</measure>
    <time_frame>45 Days</time_frame>
    <description>Change in composite safety assessment by clinical laboratory testing (full blood count, biochemistry, coagulation, iron study, CSF analysis and ECG), physical examination and reported adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microglial Activation in the Motor Cortex</measure>
    <time_frame>8 Days</time_frame>
    <description>Change in microglial activation in the motor cortex in two (2) dose cohorts, utilising serial [18F]FEMPA PET imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diffusion Kurtosis Using MRI Scan</measure>
    <time_frame>8 Days</time_frame>
    <description>Change in diffusion kurtosis using MRI scan of the brain to determine whether the blood brain barrier integrity can be measured in ALS by Magnetic Resonance Imaging, and whether 3K3A-APC is able to repair it</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocyte Activation</measure>
    <time_frame>45 Days</time_frame>
    <description>Change in the level of monocyte activation in the peripheral blood utilising a novel method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine Level</measure>
    <time_frame>45 Days</time_frame>
    <description>Change in cytokine level in serum, plasma and CSF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemokine Level</measure>
    <time_frame>45 Days</time_frame>
    <description>Change in chemokine level in serum, plasma and CSF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurofilament Level</measure>
    <time_frame>45 Days</time_frame>
    <description>Change in neurofilament level in serum, plasma and CSF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble CD14 Level</measure>
    <time_frame>45 Days</time_frame>
    <description>Change in soluble CD14 level in serum, plasma and CSF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kynurenine Level</measure>
    <time_frame>45 Days</time_frame>
    <description>Change in kynurenine level in serum, plasma and CSF.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>15mg Dose Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a fixed dose regimen of five doses of 15mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30mg Dose Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a fixed dose regimen of five doses of 30mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3K3A-APC Protein</intervention_name>
    <description>3K3A-APC with intravenous dosing of five doses of either 15mg or 30mg at 12 hourly interval. The first 8 patients will receive 15mg dose, and the next 8 patients will receive 30mg dose.</description>
    <arm_group_label>15mg Dose Group</arm_group_label>
    <arm_group_label>30mg Dose Group</arm_group_label>
    <other_name>3K3A-APC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have clinically definite ALS (Awaji Criteria)&#xD;
&#xD;
          2. Male or female age 18 years and less than 75 years at time of ALS study&#xD;
&#xD;
          3. Symptom onset less than 36 months before screening&#xD;
&#xD;
          4. Diagnosis of ALS less than 24 months before screening&#xD;
&#xD;
          5. Clinically definite Upper Motor Neuron signs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current treatment with anticoagulants (e.g., warfarin, novel oral anticoagulants,&#xD;
             heparin) that might preclude safe completion of the lumbar puncture&#xD;
&#xD;
          2. Condition that precludes the safe performance of routine lumbar puncture, such as&#xD;
             prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant&#xD;
             coagulopathy or thrombocytopenia&#xD;
&#xD;
          3. Use of investigational drugs or devices within 60 days prior to Baseline (dietary&#xD;
             supplements taken outside of a clinical trial are not exclusionary, e.g., coenzyme&#xD;
             Q10)&#xD;
&#xD;
          4. Prolonged prothrombin time or activated partial thromboplastin time &gt;2xULN&#xD;
&#xD;
          5. Severe hypertension or hypotension&#xD;
&#xD;
          6. Glomerular filtration rate (GFR) &lt;35 mL/min&#xD;
&#xD;
          7. Forced vital capacity (FVC) at screening of &lt;50% of predicted&#xD;
&#xD;
          8. Prior exposure to any exogenous form of APC&#xD;
&#xD;
          9. Inability to lie flat for procedures (MRI, PET, LP)&#xD;
&#xD;
         10. Pregnant or lactating during the study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominic Rowe, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Macquarie University, Australia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard Gan, MN, BSc(Med)</last_name>
    <phone>+61 2 9812 3739</phone>
    <email>richard.gan@mq.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paula Ordonez Artunduaga, BSc</last_name>
    <phone>+61 2 9812 3049</phone>
    <email>paula.ordonezartunduaga@mq.edu.au</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>September 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>MND</keyword>
  <keyword>Motor Neurone Disease</keyword>
  <keyword>3K3A-APC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

